Clinical Trial: A Phase I Study to Investigate the Effects of Renal Impairment on the Pharmacokinetics, Safety, and Tolerability of Opemalirsen (AZD2373)

U.S., Sept. 5 -- ClinicalTrials.gov registry received information related to the study (NCT07154901) titled 'A Phase I Study to Investigate the Effects of Renal Impairment on the Pharmacokinetics, Safety, and Tolerability of Opemalirsen (AZD2373)' on July 28.

Brief Summary: This study is being conducted to investigate the PK, safety, and tolerability of opemalirsen in participants with renal impairment, compared to participants with normal renal function.

Study Start Date: Aug. 18

Study Type: INTERVENTIONAL

Condition: Renal Impairment

Intervention: DRUG: Opemalirsen (AZD2373)

Single, subcutaneous injection of AZD2373

Recruitment Status: RECRUITING

Sponsor: AstraZeneca

Published by HT Digital Content Services with permission from ...